CONCORDBIO / Q3-FY26 / claim-ledger

Audit the questions that mattered.

Concord Biotech · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ3-FY26 · 2026-02-10Back to quarter ↗

Questions audited

Answered directly

77%

Numeric claims

Consistency

—

Question ledger

What was answered, and how?

Chintan City · Greek Capital

partial

Growth outlook beyond FY26 and labor code provision impact.

historically if you see we have grown at around 18% or so... we have considered you know half of the business over the next 3 to 5 years which contribute to around 6% growth... you reach to 30%... we kind of you know toned it down to say a kagger of 25%... gives us a lot of optimism that the return uh that the growth can return to the historical kaggle...

Chintan City · Greek Capital

direct

Injectable facility domestic marketing costs and margin impact.

No. Uh not really because uh you know uh we already have uh field force for the for the critical care uh division and um you know close to around 100 120 uh people are there...

Chintan City · Greek Capital

direct

Recurring cost impact of new labor code.

it is going to be an incremental uh normalized cost that we will have but it won't be material enough for 10 basis point or 20 basis point increase no that will not be material enough

Rita · Quest

direct

CDMO project status and tariff impact on branded drugs.

one of our projects is already commercialized in the US... it did not cover the the brands which were already launched into the into the markets... it doesn't impact already uh launched branded products in the US.

Rita · Quest

direct

Capex guidance for this year and ahead.

generally we have a capex number of around 100 150 crores as a maintenance capex uh that's the number generally we have

Naman Bhaga · Capital

direct

Reason for gross margin contraction despite high API mix.

I think this is primarily on account of the product mix... on a 9 month basis, actually the gross margin has moved from 77% to 78%... improvement in the gross margins by 100 bits.

Naman Bhaga · Capital

partial

Reason for 14% decline in formulation business.

the way that one needs to look at on a quarter on quarter is that there could be uh areas that we have kind of uh you know uh addressed through the API... that gets reflected in our API numbers which grew at 24%.

Naman Bhaga · Capital

direct

Whether deferred sales of 20-25 cr were fully captured in Q3.

that had been fully captured which was on account of the written confirmation... that sales to that customers already started to to build on...

Naman Bhaga · Capital

direct

Injectable plant losses and Stalon setup costs.

The injectables would be close to around 10 to 12 crores and uh the Stalon cost would range anywhere between 5 to 10 crores per quarter.

Sumit Gupta · Antic Stock Broking Limited

direct

Engagement on second source supply post tariff clarity.

engagement is going on on both fronts... we have couple of products at the API level which is our own API where we are engaging with uh the innovators and I expect that maybe uh one of those projects hopefully will commercialize in this quarter.

Alankar Garud · Kota Mahindra Bank

evasive

Expectation to grow overall sales in FY26.

difficult to give you a number in terms of what the growth is going to be... we are optimistic of quarter 4... putting a number there would be challenging for me.

Alankar Garud · Kota Mahindra Bank

partial

Breakdown of API growth into pricing, volumes, new launches.

much of the growth as I said is coming from our already commercialized 28 29 products... these two products that have got launched uh have seen more of validation and exhibit batch quantities...